Search

Objective To analyze the curative effects and safety of three-year zoledronic acid ( Aclasta, injected yearly) treatment in patients with postmenopausal osteoporosis. Methods The medical records of patients with postnienopausal osteoporosis, who were treated as inpatient or outpatient in the Affiliated Hospital of Qingdao University from February 2011 to June 2016, were retrospectively analyzed, and 72 patients with a mean age of 62. 5 years were included in this study. 36 patients in the control group were given calcium and VitD daily, meanwhile 36 patients in the treatment group were given the same dose of calcium and VitD daily, and intravenous dripped with zoledronic acid (5 mg) each time for 15 minutes at baseline, 12 months and 24 months. All patients were observed to 36 months. Outcomes were the changes in bone mineral density at lumbar vertebrae 1-4, femoral neck and total hip, pain scores, adverse effects, and the occurrence of new fractures in the two groups of patients. Results Patients in both groups were similar with regards to age and BMD at baseline. After treatment, BMD of each site in the treatment group increased significantly compared with the control group at the same time point (P < 0. 01). BMD at the same site in the treatment group was higher at each time point compared with the previous measurement (P < 0. 05). Pain scores at each time point in the treatment group were significantly lower compared with the control group at the same time point (P <0. 05).Pain scores of each time point in the treatment group was lower than the previous measurement (P < 0. 05 ). There were more adverse effects in the treatment group,which decreased significantly at the second and the third injections compare with the first injection. The occurrence of new fractures in treatment group was less than that of the control group. Conclusion Zoledronic acid had significant effect on the BMD,and during three years treatment, BMD had an increasing trend. Adverse effects mostly appeared within the first 3 days after injection, but at the second and the third injections, adverse effects were much less than the first injection. Using zoledronic acid three times can reduce the occurrence of new fracture. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)